Register
Login:
Share:
Email Facebook Twitter

RNS VIDEO: Reabold Resources #RBD raise £6 million and take stake in Danube Petroleum Watch here

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential


Motif Bio Share Chat (MTFB)



Share Price: 34.75Bid: 34.75Ask: 35.50Change: -0.75 (-2.11%)Faller - Motif Bio
Spread: 0.75Spread as %: 2.16%Open: 34.50High: 34.75Low: 34.50Yesterday’s Close: 35.50


Share Discussion for Motif Bio


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


leas
Posts: 3,837
Off Topic
Opinion:No Opinion
Price:35.00
RE: Leas
Fri 16:00
Ivy, those deaths would have strengthened any resolve to get the safety right. Unfortunately that is the risk in drug development. CDER do not hand out fast track approval without considering the risks. Again, as I have posted before the US and the EU have a different protocol when approving a much needed drug. In the US the benefits have to outweigh the risk. We are further down the line now in relation to that.
As an investor the risks here are not with the NDA but with the route to market and how much the company will be squeezed in achieving that.
 
Ivyspivey
Posts: 7,610
Off Topic
Opinion:No Opinion
Price:35.00
RE: Leas
Fri 15:47
E Moyer= enjoyed
Ivyspivey
Posts: 7,610
Off Topic
Opinion:No Opinion
Price:35.00
RE: Leas
Fri 15:47
Hi Leas,
Hope you e Moyer nice rise on IMM and confident this will follow suit shortly.
In fairness Kettle may not be fully aware of the changes MTFB made to the 2008 trial protocols to improve both safety and efficacy of Iclaprim as evidenced by the positive R1 and R2.
Personally don’t mind these questions unless they are repeated on a continuous basis.
Have similar average to you on IMM but bit higher here
leas
Posts: 3,837
Off Topic
Opinion:No Opinion
Price:35.00
RE: Leas
Fri 15:18
Quite right but with an avg of 29 in IMM and 32 here I don't really care. I also don't feel the need to 're invent myself when I make embarrassing statements. Why would those deaths have any bearing on the safety of REV 1 or REV 2 several years later. If there was any safety issues then those trials would have been terminated.
Kettle
Posts: 7
Off Topic
Opinion:No Opinion
Price:34.50
Leas
Fri 14:57
Well with 4 thousand posts you like the sound of your own voice but with nothing to say. I am heavily invested for me and was looking for answers of some intelligence for me to understand. Thank you for those other informed answers.
leas
Posts: 3,837
Off Topic
Opinion:No Opinion
Price:34.50
RE: Afternoon
Fri 14:49
Ivy. Comments like that are the reason I no longer post here or on IMM. Completed Back to back P3 trials. No safety issues at all. Mind blowing the shite on these bb's
AllGuesswork
Posts: 193
Off Topic
Opinion:No Opinion
Price:34.50
RE: Long memories
Fri 14:35
I don't think so. There were deaths on the trial with the standard of care drug during R2, but that's still being used all day every day.

Personally, I think there are a few issues that are holding it back - AMP, their decision to go it alone for commercialisation and the fact Iclaprim was not approved the first time around.

Admittedly, the approval is related to the safety information.

However, the switch to a constant dose and the associated increase in safety cannot be overlooked. It's a safe, effective drug.

I'm sure the FDA will see it as such with all the effort and work that has gone into the trials.

AMP will 'come good', whichever way that ends up.

They'll either succeed in going to market themselves in the US, or someone will do it for them.

So, I honestly have very little long term concern. It's just about waiting, and that's frustrating.
Ivyspivey
Posts: 7,610
Off Topic
Opinion:No Opinion
Price:34.50
Afternoon
Fri 14:32
Kettle-absolutely not.Why would you be concerned about 2009 when you heave two p3 trials finished this year with big trial protocol differences since 8 years ago and NO deaths in the latest trials in the Iclaprim group but a single death in the Vancomycin group.
These are often elderly and ill patients so to have no deaths and/or very few SAEs then the safety of Iclaprim has been totally endorsed
Kettle
Posts: 7
Off Topic
Opinion:No Opinion
Price:34.50
Long memories
Fri 14:26
Do you think the 3 deaths awhile ago is making people wary, so they think manipulation will be ignored ? That was on phase 3 I think in 2009
AllGuesswork
Posts: 193
Off Topic
Opinion:No Opinion
Price:34.50
RE: No comments today?
Fri 14:06
I think it's just a case of waiting to see what happens next.

We've discussed the fundamentals and medicine, and nothing has changed - they both look fantastic. We're expressed our incredulation at the share price compared to peers.

We've talked about the next round of news, and let's be honest, not much is going to happen this month other possibly some detailed information about R1 or maybe even just regulatory RNSs

It looks like to all intents and purposes, we're just going to have to wait and see.

The medicine is great, the share price is ludicrous, roll on Q1 and FDA submission, then we're 6 months from some real movement with a few tip bits on the way..




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.